5 Best Fundamentally Strong Penny Stocks to Invest In Now

3. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Upside Potential as of May 1, 2026: 75.70%

On April 30, TheFly reported that JPMorgan trimmed the price target on Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) from $11 to $10 and reiterated an Overweight rating. With the highest 1-year price target among analysts, the firm’s estimate implies 192.83% upside potential. Overall, the stock has a Buy rating from 38% of the analysts, with the remaining 63% neutral.

During a Morgan Stanley webcast on April 15, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) highlighted its AI-powered drug discovery platform. The leadership outlined the way technology is being utilized for target identification, molecule design, and clinical development.

According to management, AI-driven initiatives have already resulted in a 30% to 50% improvement in patient enrollment. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) also adopts AI for protocol design and patient stratification. In contrast to industry norms of 2,500 to 5,000 compounds over a span of four to five years, the company accelerated a compound to clinical trials after designing nearly 330 molecules in a period of 17 months. With a focus on AI and an impressive quarterly revenue growth (YoY) of 681.70%, RXRX is among the best fundamentally strong penny stocks to invest in now.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a Utah-based clinical-stage biotechnology company specializing in the decoding of biology and chemistry. Founded in 2013, the company develops its solutions by integrating technological advancements.